Synthetic immunotherapy seeks out and destroys tumors in mice with aggressive cancers, study finds
Latest information on COVID-19
Translating Stanford discoveries into individualized cancer care
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
Stanford researchers have developed a synthetic, tumor-targeting molecule that promotes immune activation and tumor regression in laboratory mice after it’s injected into their bloodstreams.
Stanford researcher Maria Grazia Roncarolo has been awarded $12 million by the California Institute for Regenerative Medicine for a trial aimed at improving the outcomes of stem cell transplants in children and young adults with blood cancers.
EcoTyper is an algorithm that can sort out cell “ecotypes” — distinct multicellular communities — that exist in many different kinds of cancer.
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.